Munich / Reinbek — P+P Pöllath + Partners has advised Dermapharm Holding SE on the acquisition of Allergopharma GmbH & Co KG, a subsidiary of Merck KGaA, based in Reinbek near Hamburg. Through Dermapharm Beteiligungs GmbH, the company acquires 100% of the shares in the Merck subsidiary.
The transaction is still subject to approval by the relevant regulatory authority; closing is expected by the end of the second quarter of 2020.
Dermapharm Holding SE, headquartered in Grünwald, Germany, focuses on the production and distribution of high-quality dermatological and allergological pharmaceuticals. Allergopharma is a company specialized in desensitization for allergies.
P+P Pöllath + Partners provided comprehensive legal advice to Dermapharm Holding SE in connection with the acquisition with the following multidisciplinary and multisite team:
Dr. Matthias Bruse, LL.M., Photo (Partner, Lead Partner, Corporate/M&A, Munich)
Daniel Wiedmann, LL.M. (Associated Partner, Antitrust Law, Frankfurt)
Dr. Matthias Werner (Counsel, Real Estate, Berlin)
Christine Funk, LL.M. (Senior Associate, IP/M&A, Frankfurt)
Jasmin Wagner (Senior Associate, Corporate/M&A, Munich)
Dr. Jesko von Mirbach, LL.M., EMBA (Associate, Corporate/M&A, Berlin)
Dr. Lena Hummel (Associate, Corporate/M&A, Munich)